Cargando…
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556578/ https://www.ncbi.nlm.nih.gov/pubmed/28848315 http://dx.doi.org/10.2337/ds16-0026 |